Pharmaceuticals & Biotechnology

Axsome Therapeutics, Inc. CEO pay

Herriot Tabuteau, Chief Executive Officer President and Chairman of the Board. Fiscal year 2025, as reported to the SEC.

Total compensation

$10.3M

$10,283,492 for fiscal 2025: the Summary Compensation Table total, with stock and option awards at their grant-date value.

Definitive proxy statement, filed 2026-04-24SEC accession number 0001193125-26-177610

In context

The median chief executive among 26 Pharmaceuticals & Biotechnology companies with $500M – $1B in revenue was paid $10.3M. The middle half ranged from $7.1M to $14.8M.

Herriot Tabuteau's total is at that median.

See how your pay compares to Axsome Therapeutics, Inc.'s peers

CEOSalary breaks this total into salary, bonus, stock and option awards, builds a peer set of comparable companies around it, and places your own package against them, with every figure cited to its filing.

Start a 3-day trial

Source: Axsome Therapeutics, Inc.'s definitive proxy statement (SEC Form DEF 14A), Summary Compensation Table, fiscal year 2025. Figures are as reported by the company and are not adjusted or estimated. Context figures are from CEOSalary's snapshot of SEC filings as of 2026-11-01. Not financial, legal or compensation-consulting advice.